文献速递泌尿生殖介入腹部US

经皮射频消融是治疗小肾癌的有效选择,疗效与部分肾切除术相当

Percutaneous radiofrequency ablation is an effective treatment option for small renal masses, comparable to partial nephrectomy.
PubMed 文献 · Eur Radiol · 2023-06-06

这项多中心非劣效性回顾性研究纳入2014至2021年西班牙两家医院291例小肾癌(N0M0)患者,按2:1接受经皮射频消融(PRFA,111例)或部分肾切除术(PN,180例)。PRFA组高危手术因素显著更多,但两组总生存、局部无复发生存及无转移生存均无显著差异,PRFA住院天数更短;作者认为在高危患者中PRFA肿瘤学结局与安全性非劣于PN。

要点

  • PRFA与PN在总生存、局部无复发生存及无转移生存上呈非劣效结果。
  • PRFA组住院天数均值1.04天,PN组3.57天,PRFA更短。
  • PRFA组高危手术因素显著更多:平均年龄64.56岁对57.47岁、孤立肾12.6%对5.6%、ASA评分≥3为36%对14.5%。

核心结论

  • 作者结论为在高危小肾癌患者中,PRFA的肿瘤学结局与安全性非劣于PN。
  • 患者接受PRFA后总生存、局部无复发生存及无转移生存较PN未见改善。

研究设计与样本

  • 多中心非劣效性研究,回顾性分析291例小肾癌(N0M0)患者,2014至2021年从西班牙安达卢西亚公共卫生系统两家医院前瞻性招募。
  • 患者按2:1接受PN或PRFA,其中PRFA组111例、PN组180例,均为连续患者。
  • 采用t检验、Wilcoxon-Mann-Whitney U检验、卡方检验、Fisher检验及Cochran-Armitage趋势检验比较治疗特征,用Kaplan-Meier曲线描绘总生存、局部无复发生存及无转移生存率。
  • PRFA在对比增强能量超声引导下进行。

临床应用与阅片要点

  • 原文指出该研究有直接临床应用价值,证明射频消融是小肾癌患者有效且不复杂的治疗选择。
  • 对比增强能量超声引导下PRFA为T1肾肿瘤提供了有效治疗。
  • 原文未据此给出具体阅片或报告推荐。

局限性

  • 局限性包括回顾性设计。
  • 局限性包括统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The standard therapy for small renal masses (SRMs) remains partial nephrectomy (PN), which is associated with relatively high morbidity and complication rate. Therefore, percutaneous radiofrequency ablation (PRFA) emerges as an alternative therapy. This study aimed to compare the efficacy, safety, and oncological outcomes of PRFA versus PN.

METHODS: A multicenter non-inferiority study with retrospective analysis of 291 patients with SRMs (N0M0), who underwent PN or PRFA (2:1), recruited prospectively from two hospitals in the Andalusian Public Health System, Spain, between 2014 and 2021. Comparisons of treatment features were evaluated using the t test, Wilcoxon-Mann-Whitney U test, chi-square test, Fisher test, and Cochran-Armitage trend test. Kaplan-Meier curves depicted overall survival (OS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS) rates in the overall study population.

RESULTS: A total of 291 consecutive patients were identified; 111 and 180 patients underwent PRFA and PN, respectively. Median follow-up time was 38 and 48 months, and mean hospitalization days were 1.04 and 3.57 days, respectively. The variables underpinned with high surgical risk were significantly increased in PRFA compared to those in PN (mean age was 64.56 and 57.47 years, the solitary kidney presence was 12.6% and 5.6%, ASA score ≥ 3 was 36% and 14.5%, respectively). The rest of oncological outcomes were comparable amongst PRFA and PN. Patients undergoing PRFA did not improve OS, LRFS, and MFS compared to those undergoing PN. Limitations comprise retrospective design and limited statistical power.

CONCLUSION: PRFA for SMRs in high-risk patients is non-inferior in terms of oncological outcomes and safety compared to PN.

CLINICAL RELEVANCE STATEMENT: Our study has a direct clinical application as it proves that radiofrequency ablation is an effective and uncomplicated therapeutic option for patients with small renal masses.

KEY POINTS: •There are non-inferiority results in overall survival, local recurrence-free survival, and metastasis-free survival between PRFA and PN. •Our two-center study showed that PRFA is non-inferior to PN in oncological outcomes. •Contrast-enhanced power ultrasound-guided PRFA provides an effective therapy for T1 renal tumors.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Pedraza-Sánchez, Chaves-Marcos, Mazuecos-Quirós, et al. Percutaneous radiofrequency ablation is an effective treatment option for small renal masses, comparable to partial nephrectomy. Eur Radiol. 2023. PMID: 37280356. doi:10.1007/s00330-023-09779-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。